BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1379 related articles for article (PubMed ID: 34391509)

  • 21. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
    Ström P; Nordström T; Aly M; Egevad L; Grönberg H; Eklund M
    Eur Urol; 2018 Aug; 74(2):204-210. PubMed ID: 29331214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate.
    Kohestani K; Månsson M; Arnsrud Godtman R; Stranne J; Wallström J; Carlsson S; Hellström M; Hugosson J
    Scand J Urol; 2021 Apr; 55(2):116-124. PubMed ID: 33612068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms.
    Nordström T; Engel JC; Bergman M; Egevad L; Aly M; Eklund M; Palsdottir T; Grönberg H
    Eur Urol Open Sci; 2021 Feb; 24():11-16. PubMed ID: 34337490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of replacing PSA with Stockholm3 for diagnosis of clinically significant prostate cancer in a healthcare system - the Stavanger experience.
    Viste E; Vinje CA; Lid TG; Skeie S; Evjen-Olsen Ø; Nordström T; Thorsen O; Gilje B; Janssen EAM; Kjosavik SR
    Scand J Prim Health Care; 2020 Sep; 38(3):315-322. PubMed ID: 32772613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Evaluation of Screening Pathways Using a Combination of Magnetic Resonance Imaging and Prostate-specific Antigen: Results from the IP1-PROSTAGRAM Study.
    Eldred-Evans D; Tam H; Sokhi H; Padhani AR; Connor M; Price D; Gammon M; Klimowska-Nassar N; Burak P; Day E; Winkler M; Fiorentino F; Ahmed HU
    Eur Urol Oncol; 2023 Jun; 6(3):295-302. PubMed ID: 37080821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study.
    Rouvière O; Puech P; Renard-Penna R; Claudon M; Roy C; Mège-Lechevallier F; Decaussin-Petrucci M; Dubreuil-Chambardel M; Magaud L; Remontet L; Ruffion A; Colombel M; Crouzet S; Schott AM; Lemaitre L; Rabilloud M; Grenier N;
    Lancet Oncol; 2019 Jan; 20(1):100-109. PubMed ID: 30470502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory study.
    Grey ADR; Scott R; Shah B; Acher P; Liyanage S; Pavlou M; Omar R; Chinegwundoh F; Patki P; Shah TT; Hamid S; Ghei M; Gilbert K; Campbell D; Brew-Graves C; Arumainayagam N; Chapman A; McLeavy L; Karatziou A; Alsaadi Z; Collins T; Freeman A; Eldred-Evans D; Bertoncelli-Tanaka M; Tam H; Ramachandran N; Madaan S; Winkler M; Arya M; Emberton M; Ahmed HU
    Lancet Oncol; 2022 Mar; 23(3):428-438. PubMed ID: 35240084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incorporating Magnetic Resonance Imaging and Biomarkers in Active Surveillance Protocols - Results From the Prospective Stockholm3 Active Surveillance Trial (STHLM3AS).
    Olsson H; Nordström T; Jäderling F; Egevad L; Vigneswaran HT; Annerstedt M; Grönberg H; Eklund M; Lantz A
    J Natl Cancer Inst; 2021 May; 113(5):632-640. PubMed ID: 32866231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.
    Bancroft EK; Page EC; Brook MN; Thomas S; Taylor N; Pope J; McHugh J; Jones AB; Karlsson Q; Merson S; Ong KR; Hoffman J; Huber C; Maehle L; Grindedal EM; Stormorken A; Evans DG; Rothwell J; Lalloo F; Brady AF; Bartlett M; Snape K; Hanson H; James P; McKinley J; Mascarenhas L; Syngal S; Ukaegbu C; Side L; Thomas T; Barwell J; Teixeira MR; Izatt L; Suri M; Macrae FA; Poplawski N; Chen-Shtoyerman R; Ahmed M; Musgrave H; Nicolai N; Greenhalgh L; Brewer C; Pachter N; Spigelman AD; Azzabi A; Helfand BT; Halliday D; Buys S; Ramon Y Cajal T; Donaldson A; Cooney KA; Harris M; McGrath J; Davidson R; Taylor A; Cooke P; Myhill K; Hogben M; Aaronson NK; Ardern-Jones A; Bangma CH; Castro E; Dearnaley D; Dias A; Dudderidge T; Eccles DM; Green K; Eyfjord J; Falconer A; Foster CS; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Lilja H; Lindeman GJ; Lubinski J; Axcrona K; Mikropoulos C; Mitra AV; Moynihan C; Ni Raghallaigh H; Rennert G; Collier R; ; Offman J; Kote-Jarai Z; Eeles RA
    Lancet Oncol; 2021 Nov; 22(11):1618-1631. PubMed ID: 34678156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial.
    Grenabo Bergdahl A; Wilderäng U; Aus G; Carlsson S; Damber JE; Frånlund M; Geterud K; Khatami A; Socratous A; Stranne J; Hellström M; Hugosson J
    Eur Urol; 2016 Oct; 70(4):566-573. PubMed ID: 26724840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
    Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
    Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Re: Prostate Cancer Screening Using a Combination of Risk-prediction, MRI, and Targeted Prostate Biopsies (STHLM3-MRI): A Prospective, Population-based, Randomised, Open-label, Non-inferiority Trial.
    Raslan M; Mercader C; Lamb AD
    Eur Urol; 2022 May; 81(5):543-544. PubMed ID: 35105477
    [No Abstract]   [Full Text] [Related]  

  • 35. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
    Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
    Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Capio Prostate Cancer Center Model for Prostate Cancer Diagnostics-Real-world Evidence from 2018 to 2022.
    Palsdottir T; Söderbäck H; Jäderling F; Bergman M; Vigneswaran H; Grönberg H
    Eur Urol Open Sci; 2024 Mar; 61():29-36. PubMed ID: 38384438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate cancer screening in the fit Chilean elderly: a head to head comparison of total serum PSA versus age adjusted PSA versus primary circulating prostate cells to detect prostate cancer at initial biopsy.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
    Asian Pac J Cancer Prev; 2015; 16(2):601-6. PubMed ID: 25684494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.
    Hoeks CM; Schouten MG; Bomers JG; Hoogendoorn SP; Hulsbergen-van de Kaa CA; Hambrock T; Vergunst H; Sedelaar JP; Fütterer JJ; Barentsz JO
    Eur Urol; 2012 Nov; 62(5):902-9. PubMed ID: 22325447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The SmartTarget Biopsy Trial: A Prospective, Within-person Randomised, Blinded Trial Comparing the Accuracy of Visual-registration and Magnetic Resonance Imaging/Ultrasound Image-fusion Targeted Biopsies for Prostate Cancer Risk Stratification.
    Hamid S; Donaldson IA; Hu Y; Rodell R; Villarini B; Bonmati E; Tranter P; Punwani S; Sidhu HS; Willis S; van der Meulen J; Hawkes D; McCartan N; Potyka I; Williams NR; Brew-Graves C; Freeman A; Moore CM; Barratt D; Emberton M; Ahmed HU
    Eur Urol; 2019 May; 75(5):733-740. PubMed ID: 30527787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive: The Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) Study.
    Elkhoury FF; Felker ER; Kwan L; Sisk AE; Delfin M; Natarajan S; Marks LS
    JAMA Surg; 2019 Sep; 154(9):811-818. PubMed ID: 31188412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 69.